Xenon Pharmaceut Stock Price, News & Analysis

Xenon Pharmaceuticals (Nasdaq:XENE) reported promising insights from its Phase 2b X-TOLE clinical trial for XEN1101, showing significant reductions in focal seizure frequency among adult patients. The therapy is designed for easy administration with once-daily dosing. With $249.6 million in cash and equivalents as of September 30, 2021, and anticipated cash flow until at least 2024, the company is set for the initiation of its Phase 3 trial in adult focal epilepsy in late 2022. Total revenue for Q3 2021 reached $8.1 million, up from $6.6 million a year earlier.

Xenon Pharmaceuticals (Nasdaq:XENE) will report its third quarter 2021 financial results on November 10, 2021, after U.S. market close. A live conference call and webcast will take place at 4:30 pm ET to discuss these results and provide a corporate update. Investors can access the webcast through the company's website. As a clinical-stage biopharmaceutical company, Xenon focuses on developing therapies for neurological disorders, particularly epilepsy, addressing significant unmet medical needs.

Xenon Pharmaceuticals Inc. has successfully closed its underwritten public offering of 10,000,000 common shares, including 1,525,423 shares from the underwriters’ option, and pre-funded warrants for 1,694,915 shares. The shares were priced at $29.50 each, with pre-funded warrants at $29.4999. The gross proceeds from this offering totaled approximately $345 million, prior to expenses. The offering followed an effective shelf registration statement filed with the SEC on October 4, 2021.

Xenon Pharmaceuticals has announced a public offering of 8,474,577 common shares and 1,694,915 pre-funded warrants, priced at $29.50 and $29.4999 respectively. The offering aims to raise approximately $300 million in gross proceeds, which will support the company's clinical stage developments. The offering is set to close on or about October 8, 2021. The underwriters have a 30-day option to purchase an additional 1,525,423 shares at the offering price. Jefferies, SVB Leerink, Stifel, and RBC Capital Markets are leading the offering.

Xenon Pharmaceuticals Inc. (Nasdaq: XENE) has initiated an underwritten public offering of $250 million in common shares, with an option for underwriters to purchase an additional $37.5 million. The offering is made under an existing shelf registration statement filed with the SEC. Notably, this process is subject to market conditions, and completion is not guaranteed. Notable underwriters include Jefferies, SVB Leerink, Stifel, and RBC Capital Markets. The company emphasizes that no securities are being offered in Canada.

Xenon Pharmaceuticals (Nasdaq:XENE) reported promising results from its Phase 2b X-TOLE clinical trial for XEN1101, aimed at treating focal epilepsy. The trial showcased statistically significant reductions in monthly focal seizure frequency across all dose groups, with p-values under 0.001 for the 20 mg and 25 mg doses. A median reduction of 52.8% was noted for the highest dose, compared to 18.2% for placebo. The encouraging outcomes support XEN1101's efficacy and safety, with plans to collaborate with the FDA for expedited development and a long-term study extension now set for three years.

Xenon Pharmaceuticals (Nasdaq:XENE) will host a conference call and webcast on October 4, 2021, at 7:30 AM ET to discuss topline results from the XEN1101 Phase 2b “X-TOLE” clinical trial. Investors can join the conference call by dialing (855) 779-9075 in the U.S. or (631) 485-4866 internationally, using conference ID number 4481713. The call will be available on the Xenon website for replay after the event. Xenon is focused on developing innovative treatments for neurological disorders, particularly epilepsy.

Xenon Pharmaceuticals announced a $10 million milestone payment from Neurocrine Biosciences after gaining regulatory approval for a clinical trial application in Europe. This payment includes $4.5 million in cash and a $5.5 million equity investment at a premium price of $19.9755 per share. Xenon collaborates with Neurocrine on NBI-921352, aimed at treating focal-onset seizures and SCN8A developmental and epileptic encephalopathy. Phase 2 trials for both conditions are expected to begin later in 2021, reflecting progress in epilepsy treatment options.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE) has appointed Dr. Christopher Kenney as Chief Medical Officer. Dr. Kenney will lead clinical development and medical affairs strategies for the company's neurology-focused therapeutic programs. CEO Ian Mortimer expressed optimism about Dr. Kenney's extensive experience in clinical development and neuroscience, especially as the company prepares for the topline data from its XEN1101 Phase 2b X-TOLE study, expected in late September to mid-October. Dr. Kenney has over 20 years of experience in the field, including roles at Cadent Therapeutics and Acorda Therapeutics.